Robert Elling
Novartis
8 Papers
Robert Elling is an academic researcher from Novartis. The author has contributed to research in topics: Biology & Chemistry. The author has an hindex of 7, co-authored 7 publications.
Chat about Author
Papers
Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivo
William E. Dowdle,Beat Nyfeler,Jane Nagel,Robert Elling,Shanming Liu,Ellen Triantafellow,Suchithra Menon,Zuncai Wang,Ayako Honda,Gwynn Pardee,John Cantwell,Catherine Luu,Ivan Cornella-Taracido,Edmund Harrington,Peter Fekkes,Hong Lei,Qing Fang,Mary Ellen Digan,Debra Burdick,Andrew F. Powers,Stephen B. Helliwell,Simon D’Aquin,Julie Bastien,Henry Wang,Dmitri Wiederschain,Jenny Kuerth,Philip Bergman,David Schwalb,Jason R. Thomas,Savuth Ugwonali,Fred Harbinski,John A. Tallarico,Christine D. Wilson,Vic E. Myer,Jeffery A. Porter,Dirksen E. Bussiere,Peter Finan,Mark Labow,Xiaohong Mao,Lawrence G. Hamann,Brendan D. Manning,Reginald Valdez,Thomas B. Nicholson,Markus Schirle,Mark Knapp,Erin P. Keaney,Leon Murphy +46 more
TL;DR: a4−/− mice exhibit a profound accumulation of iron in splenic macrophages, which are critical for the reutilization of iron from engulfed red blood cells, and a previously unappreciated role for autophagy and NCOA4 in the control of iron homeostasis in vivo is revealed.
643
Structure-guided enzymology of the lipid A acyltransferase LpxM reveals a dual activity mechanism.
Dustin Dovala,Christopher M. Rath,Qijun Hu,William S. Sawyer,Steven Shia,Robert Elling,Mark Knapp,Louis E. Metzger +7 more
TL;DR: This work structurally and mechanistically characterize LpxM, providing insights that may enable the targeted discovery of inhibitors that prevent lipid A maturation, and describes a high-throughput, label-free mass spectrometric assay to characterize acyltransferase enzymatic activity.
38
Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
Jiping Fu,Meiliana Tjandra,Christopher Becker,Dallas Bednarczyk,Michael Paul Capparelli,Robert Elling,Imad Hanna,Roger Aki Fujimoto,Markus Furegati,Subramanian Karur,Theresa Kasprzyk,Mark Knapp,Kwan Leung,Xiaolin Li,Peichao Lu,Wosenu Mergo,Charlotte Miault,Simon Ng,David Thomas Parker,Yunshan Peng,Silvio Roggo,Alexey Rivkin,Robert Lowell Simmons,Michael Wang,Brigitte Wiedmann,Andrew H. Weiss,Linda Xiao,Lili Xie,Wenjian Xu,Aregahegn Yifru,Shengtian Yang,Bo Zhou,Zachary Kevin Sweeney +32 more
TL;DR: In this article, the side chain hydrophobicity of the P4 residue of cyclophilin D has been reduced to preserve binding and antiviral potency while decreasing transporter inhibition.
36
Rationally Designed PI3Kα Mutants to Mimic ATR and Their Use to Understand Binding Specificity of ATR Inhibitors
Yipin Lu,Mark Knapp,Kenneth Crawford,Warne Robert L,Robert Elling,Kelly Yan,Michael Doyle,Gwynn Pardee,Li Zhang,Sylvia Ma,Mulugeta Mamo,Elizabeth Ornelas,Yue Pan,Dirksen E. Bussiere,Johanna M. Jansen,Isabel Zaror,Albert Lai,Paul A. Barsanti,Janet Sim +18 more
TL;DR: The ability to obtain structural and binding data for these PI3Kα mutants, together with their ATR-like inhibitor binding profiles, makes these chimeric PI2Kα proteins valuable model systems for structure-based inhibitor design.
28
Identification of Brain-Penetrant ATP-Competitive mTOR Inhibitors for CNS Syndromes.
Simone Bonazzi,Audrey Gray,Noel M. Thomsen,Jonathan Biag,Nancy Labbé-Giguère,Erin P. Keaney,Hasnain A. Malik,Yingchuan Sun,Jill Nunez,Rajesh Karki,Mark Knapp,Robert Elling,John Fuller,Gwynn Pardee,Lucas Craig,Ketthsy Capre,Sarah Salas,Aakruti Gorde,Gui-Lun Liang,Danuta Lubicka,Stephanie M. McTighe,Carleton P. Goold,Shanming Liu,Lin Deng,Alexander Fekete,Pascal Stadelmann,Wilfried Frieauff,Azeddine Elhajouji,Daniel Bauer,Andreas Lerchner,Branko Radetich,Pascal Furet,Grazia Piizzi,D S Burdette,Chris Wilson,Stefan Peukert,Lawrence G. Hamann,Leon Murphy,Daniel Curtis +38 more
TL;DR: In this paper , a catalytic mTOR inhibitor optimized for central nervous system (CNS) indications was proposed, which is able to block mTOR functions in the mouse brain and extend the survival of mice with neuronal-specific ablation of the Tsc1 gene.